SCHEMBL5537460

SCHEMBL5537460

[CH2]c1scc2cc(OCC)ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
HSD17B10 Q99714 2/20 0.51
MAPT P10636 2/20 0.51
NQO1 P15559 1/20 0.43
PARP15 Q460N3 1/20 0.41
PARP10 Q53GL7 1/20 0.41
TNKS2 Q9H2K2 1/20 0.41
KMT2A Q03164 4/20 0.40
MEN1 O00255 3/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 2/20 0.40
CYP3A4 P08684 2/20 0.40
TERT O14746 1/20 0.39
ABCB11 O95342 1/20 0.39
LMNA P02545 1/20 0.39
THRB P10828 1/20 0.39
BLM P54132 1/20 0.39
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
PPM1A P35813 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543995 0.86 ALDH1A1 (0.47) ALDH1A1HSD17B10MAPTNQO1PARP15
SCHEMBL5537466 0.83 ALDH1A1 (0.51) ALDH1A1HSD17B10MAPTNQO1PARP15
SCHEMBL5546364 0.80 CYP1A2 (0.45) ALDH1A1HSD17B10MAPTPARP15PARP10
SCHEMBL18417197 0.75 NQO1 (0.56) ALDH1A1HSD17B10MAPTNQO1KMT2A
SCHEMBL5534567 0.75 MAPT (0.67) ALDH1A1HSD17B10MAPTNQO1PARP15
SCHEMBL3825385 0.74 NQO1 (0.68) ALDH1A1HSD17B10MAPTNQO1KMT2A
SCHEMBL29629327 0.74 NQO1 (0.68) ALDH1A1HSD17B10MAPTNQO1KMT2A
SCHEMBL12259987 0.74 NQO1 (0.54) ALDH1A1HSD17B10MAPTNQO1KMT2A
SCHEMBL5544002 0.72 ALDH1A1 (0.47) ALDH1A1HSD17B10MAPTNQO1PARP15
SCHEMBL5538024 0.72 KIF11 (0.41) HSD17B10KMT2ATP53CYP3A4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885HSD17B10 467/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.